Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris
Angela Moore, Kara Hurley
Abstract
Pemphigus Vulgaris (PV) is a subgroup of IgG-mediated autoimmune blistering diseases targeting desmosomal adhesion proteins, desmoglein (Dsg) 1 and Dsg 3.1 Systemic corticosteroids are the current first-line treatment. Other treatments aimed at disease control include immunosuppressive and immunomodulatory agents, such as azathioprine, mycophenolate mofetil, cyclosporine, intravenous immunoglobulin, dapsone, and rituximab.
Topics & Concepts
Pemphigus vulgarisMedicineAzathioprineDapsoneRituximabDesmoglein 3ImmunologyMycophenolatePemphigusTazaroteneDermatologyAntibodyAutoantibodyDiseasePsoriasisInternal medicineTransplantationAutoimmune Bullous Skin DiseasesUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and Angioedema